NEU Neuren Pharmaceuticals Ltd
- 19.910
- -0.030-0.15%
Neuren Pharmaceuticals Ltd News
This ASX 200 Healthcare Stock Is up 48% in a Year, but One Director Is Still Buying!
AU Evening Wrap: Australia Shares Fall 0.3% Amid Commodity Weakness
Australia shares fell 0.3% amid commodity weakness. The heavyweight materials sector lost 0.9%.
Are Investors Undervaluing Neuren Pharmaceuticals Limited (ASX:NEU) By 46%?
AU Evening Wrap: Australia Shares Rise 0.8% as Bank Stocks Gain
Australia shares rise 0.8% as bank stocks gain. Nine of its eleven sectors finished higher, with the heavyweight financials' 1.5% rise at the forefront.
These ASX Shares Could Rise 25% to 35%
If you want to give your investment portfolio a nice boost, then it could be worth considering the ASX shares listed below.
AU Evening Wrap: Australia Shares Tumble 1.3% as Rate-Cut Hopes Fade
Australia shares tumbled 1.3% as rate-cut hopes faded, with all eleven sectors finishing down and consumer staples and financials leading the way.
Why Cettire, Neuren, Peter Warren, and Qantas Shares Are Falling Today
The S&P/ASX 200 Index (ASX: XJO) is having a very tough session on Wednesday. In response to the release of a hotter than expected inflation reading, the benchmark index is down 1.35% to 7,661.5 points.
Neuren Pharmaceuticals Price Target Raised 8% to A$31.29/Share by Petra Capital
Neuren Pharmaceuticals Price Target Raised 8% to A$31.29/Share by Petra Capital
This ASX 200 Stock Can Rocket to a Record High: Broker
The Neuren Pharmaceuticals Ltd (ASX: NEU) share price was in fine form on Monday.
AU Evening Wrap: Australia Shares Rise 0.8% Amid Bank, Gold Gains
Australia shares rise 0.8% amid strong gains by banks, gold miners and consumer-focused companies. Ten of eleven sectors finished higher as the benchmark index bounced from Friday's 1.1% drop, following a mostly positive lead by U.S. equities.
Market Mover | shares of Neuren Pharmaceuticals jump 11% on positive Phase 2 trial results
Neuren Pharmaceuticals Price Target Raised 13% to A$30.00/Share by Wilsons
Neuren Pharmaceuticals Price Target Raised 13% to A$30.00/Share by Wilsons
Guess Which ASX 200 Healthcare Share Just Rocketed 11% on 'groundbreaking Trial'
The S&P/ASX 200 Index (ASX: XJO) is up a very healthy 0.8% today, but this ASX 200 healthcare share is leaving those gains wanting.
Neuren Pharmaceuticals Reveals Promising Trial Results
ASX 200 Healthcare Stock up 40% in 6 Months Halted Ahead of Major Trial Results
Neuren Pharmaceuticals Ltd (ASX: NEU) requested the trading halt before the market open today.
AU Evening Wrap: Australia Shares Rise 0.35% Amid Iron-Ore Strength
Australia shares rise 0.35% amid iron-ore strength. Fortescue, Rio Tinto and BHP added between 0.85% and 2.2%.
AU Evening Wrap: Australia Shares Fall 0.3% Ahead of Budget Announcement; Critical Minerals Miners Rise
Critical mineral miners were among the best performers on the ASX, as they were expected to be among the big winners after the budget announcement.
Brokers Name 3 ASX Shares to Buy Now 10 May 2024
It has been another busy week for Australia's top brokers. This has led to the release of a number of broker notes.
Why Cettire, De Grey Mining, Life360, and Neuren Shares Are Falling Today
The S&P/ASX 200 Index (ASX: XJO) has returned to form on Friday. In afternoon trade, the benchmark index is up 0.5% to 7,759.5 points.
Daybue Guidance Looks Achievable for Acadia, Neuren -- Market Talk
0011 GMT - Acadia Pharmaceuticals' target of $370 million-$420 million net sales of its Daybue treatment for Retts Syndrome looks achievable to Jefferies, despite a small miss in 1Q. In a research not
Analysis
Price Target
No Data
